Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 6070

Next Previous
X
Search
Drug Profile

MK 6070

Alternative Names: HPN-328; MK-6070

Latest Information Update: 21 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harpoon Therapeutics
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

  • 21 Jan 2025 Merck Sharp & Dohme plans a phase I/II trial for Small cell lung cancer (Second-line therapy or greater, Late-stage disease) in February 2025 (IV, Infusion) (NCT06780137)
  • 07 Sep 2024 Updated efficacy and adverse event data from a phase I/II trial inNeuroendocrine tumors and Small-cell lung cancer presented at presented at the 25th World Conference on Lung Cancer (WCLC-2024)
  • 06 Aug 2024 Daiichi Sankyo Company and Merck enter into a co-develop and co-commercialisation agreement for MK 6070

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top